Venture Capital · San Francisco (United States), Boston (United States) · Founded 2002
5AM Ventures is a leading life science venture capital firm focused on funding and building next-generation life sciences companies. They primarily invest in early-stage private therapeutic companies, with an emphasis on Series A, and also invest in small and mid-cap public and later-stage private biotech and life science companies.
Seed, Series A, Series B
BioTech, Pharma
Achaogen (AKAO), Akouos (AKUS), Alexza (ALXA), Ambrx, Aprea (APRE), Artiva Biotherapeutics (ARTV), Arvinas (ARVN), Audentes, Bellerophon (BLPH), Bird Rock Bio, Cabaletta Bio (CABA), Calibrium, Camp4 (CAMP), Cellular Research, Ceterix, Chrono, Cidara (CDTX), CinCor (CINC), Crinetics (CRNX), Dianthus Therapeutics (DNTH), DVS, Enliven Therapeutics (ELVN), Ensoma, Entrada (TRDA), Envoy, Epirus (EPRS), Escient Pharmaceuticals, Expansion Therapeutics, Flexion (FLXN), GlycoEra, Halio, Inc., Homology Medicines, Inc. (FIXX), Ideaya Biosciences, Igenica, Ikaria, Ilypsa, Impel Neuropharma (IMPL), Incline, Inipharm, KaloBios (KBIO), Karius, Kinaset Therapeutics, Latigo, Lifordi, Magnetic Insight, Marcadia, Miikana, Millendo, nChroma Bio, Neurogastrx, Nido Bio, NodThera, Nouscom, Novira, Panomics, Pear (PEAR), Pearl, PhaseRx (PZRX), Portal, Precede Bio, PNI, Pulmatrix (PULM), Purigen, Radionetics, Rallybio (RLYB), RareCyte, Relypsa (RLYP), Rennovia, Scientist.com, scPharmaceuticals (SCPH), Semprus, Skye (SKYE), Synosia, TMRW, VBI Vaccines, Viveve (VIVE), Vor Biopharma (VOR), Wildcat